Korea's Shin Poong Seeks EMEA Special Approval For Anti-malarial Drug Pyramax
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Local South Korean drug maker Shin Poong Pharmaceutical submitted a new drug application to the European Medicines Agency for its new artemisinin combination therapy Pyramax (pyronaridine-artesunate) for malaria
You may also be interested in...
Korea’s Shin Poong Pharmaceutical Cuts Biotech Deal With France’s LFB Biotechnologies
Shin Poong and LFB agreed to set up a joint-venture biotech plant in Korea for sales of LFB biotech products in other countries
Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers
HONG KONG - The emergence across Southeast Asia of strains of malaria that display increasing tolerance to the more commonly used therapies could undo years of progress in battling the disease, and public-private partnerships are trying to respond as quickly as possible
Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers
HONG KONG - The emergence across Southeast Asia of strains of malaria that display increasing tolerance to the more commonly used therapies could undo years of progress in battling the disease, and public-private partnerships are trying to respond as quickly as possible